Areas of Interest & Competitive Research Grants - Bristol Myers Squibb
Areas of Interest (AOI)
Bristol Myers Squibb seeks Independent Research applications across all therapeutic areas. Our Areas of Interest outline additional criteria to help guide the scientific community. All concept applications submitted that best align with our interests will be considered and evaluated.
|Therapeutic Area and / or Compound||AOIs Posted on BMS.com||Pre-Concept Submission Period|
|Start Date||End date|
|Immunology – TYK2 (deucravacitinib)||20-Sep-21||18-Oct-21||19-Nov-21|
|Oncology – Relatlimab||15-Sept-21||4-Oct-21||29-Oct-21|
|Immunology – (ozanimod) Ulcerative colitis||31-May-21||31-May-21||23-Jul-21|
|Cardiovascular – (mavacamten) Hypertrophic Cardiomyopathy||10-May-21||14-Jun-21||9-Jul-21|
|Immunology – (ozanimod) Multiple Sclerosis||26-Mar-21||3-May-21||21-May-21|
Filter by the Therapeutic Area field & Disease Area field below to find related Areas of Interest:
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.
- If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here
- If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
- If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
- If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
- If you are a potential investigator who is interested in seeking support for independent research involving NKTR-214 (Bempegaldesleukin) & Nivolumab, click here
Melanoma – Relatlimab ISR Areas of Interest – 2021 RFP Cycle 1
- Relatlimab + Nivolumab or other Relatlimab + Nivolumab-based combinations in metastatic patients with the highest unmet need (i.e., brain metastasis, high LDH, >3 sites of disease, poor PS, post PD1, non-cutaneous, etc.) regardless of BRAF status and line of therapy
- Understand biomarkers and translational mechanisms of response, resistance, and adverse events to Relatlimab + Nivolumab-based combinations
- Neoadjuvant/peri-adjuvant research with Relatlimab + nivolumab-based combinations, regardless of BRAF status, to understand tumor biology and improve patient outcomes
- Sequencing with Relatlimab + Nivolumab relative to other therapies (re-treatment and switch), regardless of BRAF status
Out of scope:
- Pediatric studies
- Studies investigating non-melanoma tumors
- Studies investigating Relatlimab as monotherapy
- Studies only including Nivolumab ± Ipilimumab in melanoma (Nivolumab ± Ipilimumab as comparator arm allowed)
- Each individual drug in Relatlimab + Nivolumab-based combination must have established phase 2 dose, otherwise considered out of scope
TYK2 (deucravacitinib) AOIs – RFP#2
- Deucravacitinib efficacy and safety in moderate to severe psoriasis, including patient sub-populations
- Demographics (e.g., ethnicity, race)
- Body regions
- Psoriasis treatments (e.g., Systemic treatment naïve, switching from or adding on to topical therapy, switching from other oral systemic therapies
- Additional measures of response (eg, patient satisfaction, other Patient-Reported Outcomes)
- Clinical and biomarker proof-of-concept evidence with deucravacitinib in other dermatological immune-mediated diseases with evidence of involvement of TYK2-mediated pathways
- Nonclinical studies furthering the understanding of the role of TYK2 in immune mediated diseases
Out of scope
- Pediatric studies
- Combination with other disease modifying therapies
- Alternative dosing regimens
FOR CAR T ASSETS
- Based on the current manufacturing capacity for CAR T products, we are unable to consider ISR proposals that require the provision of CAR T product at this time.
- We are accepting ISR proposals for CAR T based on the following Areas of Interest (AOIs)
- Decipher the optimal treatment sequence with liso-cel in DLBCL through real world evidence
- What is the optimal sequencing of liso-cel with other available treatments?
- What are the outcomes for patients who proceed to other therapies post liso-cel failure?
- Identify optimal bridging strategies to liso-cel in DLBCL including through real world evidence
- Evaluate outcomes in patients treated with liso-cel or other CAR T through real world evidence
- What are the outcomes in the commercial setting vs clinical trials?
- What are the outcomes for those who do not experience grade 3+ CRS / NT, or other AEs?
- Do interventions for CRS / NT (e.g., steroids, tocilizumab) impact outcomes?
- Evaluate use of ide-cel in triple class exposed RRMM through real world evidence
- Evaluate predictors of response
- Assess impact of bridging therapy
- Understand longer-term outcomes with ide-cel
- Evaluate safety profile to inform setting of care decisions through real world evidence
- Assess mitigation and monitoring strategies for CRS & NT
- Evaluate site of care and timing of release from hospital
- Assess impact of long-term cytopenias
- Evaluate sequencing in RRMM through real world evidence
- Assess sequencing of ide-cel with respect to other anti-BCMA assets
- Evaluate impact of prior treatments
- Assess outcomes of patients who receive other therapies post ide-cel failure
If you are an investigator who is interested in seeking support for independent research relating to CAR T (ide-cel or liso-cel), click here